Immunohistochemical expression of β‐catenin, E‐cadherin, cyclin D1 and c‐myc in benign trichogenic tumors

Demirkan, Neşe Çallı; Bir, Ferda; Erdem, Özlem; Düzcan, Ender

doi:10.1111/j.1600-0560.2006.00636.x

Cited by 19 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On this basis, we suggest that the Wnt signaling pathway is not involved in the trichofolliculoma and trichoepithelioma development. These data are paralleled by Demirkan et al who detected no β-catenin gene mutation in other benign trichogenic tumors except of pilomatrixomas 26 . To support this hypothesis, c-myc and cyclin D1 expressions were analyzed in tumors (data not shown).…”

Section: Discussionsupporting

confidence: 74%

Immunohistochemical assessment of E-cadherin and β-catenin in trichofolliculomas and trichoepitheliomas

Bezděková¹,

Brychtová²,

Sedláková³

et al. 2007

BIOMED PAP

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 74%

Immunohistochemical assessment of E-cadherin and β-catenin in trichofolliculomas and trichoepitheliomas

Bezděková¹,

Brychtová²,

Sedláková³

et al. 2007

BIOMED PAP

View full text Add to dashboard Cite

“…5,10,14,17 Similar to pilomatrixoma, activating mutations of the Wnt signaling pathway have been found in this malignant variant suggesting the possibility of malignant transformation. 12,18,19 Mutations in the CTNNB1 gene, which encodes beta-catenin, 25 a downstream effector in the Wnt signaling pathway which is involved in cell differentiation, proliferation and adhesion, 26 leads to the development of tumors of hair matrix differentiation. 18,19,[26][27][28] It is plausible that initiating betacatenin mutations result in the formation of pilomatrixomas in younger patients which over time, with additional mutations in some tumor suppressor and/or proto-oncogenes, impart malignant potential and the formation of pilomatrix carcinoma in the elder patients.…”

Section: Discussionmentioning

confidence: 99%

Pilomatrix carcinoma: 12‐year experience and review of the literature

Jones

Twoon

et al. 2017

J Cutan Pathol

View full text Add to dashboard Cite

Pilomatrix carcinoma is a rare, locally aggressive tumor with a tendency to recur. Distant metastases have been reported, with pulmonary lesions being the most frequent manifestation. Similar to pilomatrixoma, pilomatrix carcinoma typically presents as a nontender, firm dermal swelling and is found most commonly in the head and neck region. Although pilomatrixomas and pilomatrix carcinoma are well-recognized lesions, clinically they are frequently misdiagnosed as other skin conditions. By reviewing the literature over the past 10 years, the aims of this review are to analyze the cause, clinical presentation, histopathologic features, management and outcomes of pilomatrix carcinoma amongst children and adults. Pilomatrix carcinoma is a rare, locally aggressive tumor with a tendency to recur. 6-8 Distant metastases have been reported, with pulmonary lesions being the most frequent manifestation. 7-10 Similar to pilomatrixoma, pilomatrix carcinoma typically presents as a nontender, firm dermal swelling [3][4][5][6]8,11 and is found most commonly in the head and neck region. 9,11In contrast to benign pilomatrixomas, which show a bimodal occurrence with a slight female predominance, 2,5 pilomatrix carcinoma commonly occurs in the 5th to the 7th decade with a male to female ratio of 4:1. 9,12Given its rarity, a gold standard treatment regimen has not been established, however, most studies recommend wide local excision with or without adjuvant radiotherapy.

show abstract

“…Beta-catenin is a downstream effector in the Wnt-signalling pathway that is involved in cell differentiation, proliferation, and adhesion. 32,33 In fact, activating mutations in beta-catenin regulation have been observed in 75% of pilomatrixomas, suggesting an association of the two. 21 Although this mechanism is not proven, considering both DM and pilomatrixomas are uncommon conditions, it is unlikely that this association between the two is a chance occurrence.…”

Section: Discussionmentioning

confidence: 99%

Pilomatrix Carcinoma in a Patient With Type 1 Myotonic Dystrophy: A Case Report

Zhu

Choi

Santos

et al. 2020

Plastic Surgery Case Studies

View full text Add to dashboard Cite

This is the first report of pilomatrix carcinoma in a man with C282Y myotonic dystrophy type 1. This pilomatrix carcinoma had originally presented as a rapidly growing recurrence of a histopathologically confirmed pilomatrixoma, removed a year prior. On examination, the fungating mass had measured 10 × 23 cm. A wide local resection with removal of suspicious lymph nodes was preformed, and the resulting defect was reconstructed with a latissimus dorsi myocutaneous flap and skin graft. Histologic investigation of the excised mass confirmed the diagnosis of pilomatrix carcinoma. This is the first reported case of pilomatrix carcinoma in a patient with a genetic condition that often presents with scalp pilomatrixomas. Potential implications of myotonic dystrophy on developing pilomatrix carcinoma are discussed.

show abstract

Immunohistochemical expression of β‐catenin, E‐cadherin, cyclin D1 and c‐myc in benign trichogenic tumors

Abstract: In PMX, nuclear and/or cytoplasmic beta-catenin expression of tumoral cells is not related with beta-catenin-related gene expressions (c-myc or cyclin D1). The molecular behaviour of OBTTs is clearly different from that of PMXs in terms of to E-cadherin and beta-catenin expression.

Cited by 19 publications

References 37 publications

Immunohistochemical assessment of E-cadherin and β-catenin in trichofolliculomas and trichoepitheliomas

Immunohistochemical assessment of E-cadherin and β-catenin in trichofolliculomas and trichoepitheliomas

Pilomatrix carcinoma: 12‐year experience and review of the literature

Pilomatrix Carcinoma in a Patient With Type 1 Myotonic Dystrophy: A Case Report

Contact Info

Product

Resources

About